Novel drugs, like selective dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes, might have fewer side effects than metformin and other anti-diabetic medication. This evidence concerns the gene DPP4 and type 2 diabetes mellitus.